A detailed history of Rhumbline Advisers transactions in Nkarta, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 79,056 shares of NKTX stock, worth $185,781. This represents 0.0% of its overall portfolio holdings.

Number of Shares
79,056
Previous 84,011 5.9%
Holding current value
$185,781
Previous $496,000 28.02%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$4.52 - $8.0 $22,396 - $39,640
-4,955 Reduced 5.9%
79,056 $357,000
Q2 2024

Aug 01, 2024

BUY
$5.27 - $10.82 $174,526 - $358,325
33,117 Added 65.07%
84,011 $496,000
Q1 2024

May 09, 2024

BUY
$5.59 - $15.71 $8,742 - $24,570
1,564 Added 3.17%
50,894 $550,000
Q3 2023

Nov 09, 2023

SELL
$1.39 - $2.29 $275 - $453
-198 Reduced 0.4%
49,330 $68,000
Q2 2023

Aug 08, 2023

SELL
$2.19 - $5.17 $3,740 - $8,830
-1,708 Reduced 3.33%
49,528 $108,000
Q1 2023

May 11, 2023

SELL
$3.37 - $6.3 $1,513 - $2,828
-449 Reduced 0.87%
51,236 $182,000
Q4 2022

Feb 14, 2023

BUY
$5.14 - $14.35 $4,343 - $12,125
845 Added 1.66%
51,685 $310,000
Q3 2022

Nov 10, 2022

BUY
$12.27 - $18.39 $34,466 - $51,657
2,809 Added 5.85%
50,840 $669,000
Q2 2022

Aug 11, 2022

BUY
$7.77 - $19.44 $233,978 - $585,396
30,113 Added 168.06%
48,031 $592,000
Q1 2022

May 12, 2022

SELL
$8.66 - $14.99 $14,297 - $24,748
-1,651 Reduced 8.44%
17,918 $204,000
Q4 2021

Feb 10, 2022

SELL
$12.79 - $26.88 $6,497 - $13,655
-508 Reduced 2.53%
19,569 $300,000
Q3 2021

Nov 12, 2021

BUY
$26.67 - $38.76 $18,002 - $26,163
675 Added 3.48%
20,077 $558,000
Q2 2021

Aug 05, 2021

SELL
$23.94 - $36.68 $35,143 - $53,846
-1,468 Reduced 7.03%
19,402 $615,000
Q1 2021

May 06, 2021

BUY
$31.33 - $59.61 $71,213 - $135,493
2,273 Added 12.22%
20,870 $687,000
Q4 2020

Feb 10, 2021

BUY
$27.03 - $75.62 $86,468 - $241,908
3,199 Added 20.78%
18,597 $1.14 Million
Q3 2020

Nov 12, 2020

BUY
$23.52 - $47.9 $362,160 - $737,564
15,398 New
15,398 $463,000

Others Institutions Holding NKTX

About Nkarta, Inc.


  • Ticker NKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,656,800
  • Market Cap $114M
  • Description
  • Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...
More about NKTX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.